Korsana Biosciences is officially a public company.

‍

The biotech has completed its merger with Cyclerion Therapeutics and secured $380 million in private financing. The combined company is keeping the Korsana name and now trades on the Nasdaq under the ticker “KRSA.”

‍

If you’re unfamiliar, Korsana is developing treatments for neurodegenerative diseases, starting with an experimental Alzheimer's drug called KRSA-028. And it's taking a somewhat different approach to one of the biggest problems facing Alzheimer's drugs today: getting enough medicine into the brain.

‍

KRSA-028 is an antibody designed to target amyloid beta, the protein that accumulates into plaques in the brains of people with Alzheimer's disease. That's similar to the basic strategy behind newer Alzheimer's drugs such as Leqembi and Kisunla.

‍

Korsana is trying to improve on that approach.

‍

The company has developed what's essentially a shuttle for carrying the drug across the blood-brain barrier, the protective layer that prevents many substances in the bloodstream from easily entering the brain. Its THETA technology uses the transferrin receptor, a naturally occurring pathway into the brain, to potentially deliver substantially more of the antibody where it's needed.

‍

If it works, Korsana believes KRSA-028 could remove amyloid plaques while improving upon some of the limitations of existing treatments, including safety and convenience. The drug is also being designed for low-volume injections under the skin, rather than relying solely on lengthy intravenous infusions.

‍

Plenty of cash

‍

Korsana expects Phase 1 data from healthy volunteers around mid-2027. The first data showing whether the drug can actually clear amyloid plaques in Alzheimer's patients are expected near the end of 2027 or during the first quarter of 2028.

‍

At least Korsana has plenty of money to find out.

‍

The $380 million financing, combined with existing cash, leaves the company with approximately $475 million in cash and cash equivalents on a pro forma basis. Management expects that to fund operations into 2029 and carry Korsana through several important clinical milestones.

‍

So for now, Korsana is essentially a well-funded bet on a better way to deliver Alzheimer's drugs into the brain.

‍

We won't know whether that bet pays off for quite some time. But with nearly half a billion dollars available and its first human data expected next year, Korsana should have enough money to give KRSA-028 a legitimate shot.

‍